Jacobs Levy Equity Management’s BridgeBio Pharma BBIO Stock Holding History

Jacobs Levy Equity Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.69M	Buy	+63,180	New	+$4.58M	0.02%	428
2023 Q1	–	Sell	-1,283,990	Closed	-$9.78M	–	963
2022 Q4	$9.78M	Buy	1,283,990 +83,912	+7%	+$803K	0.07%	283
2022 Q3	$11.9M	Buy	1,200,078 +1,131,993	+1,663%	+$11.8M	0.09%	229
2022 Q2	$618K	Buy	+68,085	New	+$569K	﹤0.01%	839
2020 Q4	–	Sell	-5,422	Closed	-$203K	–	1017
2020 Q3	$203K	Sell	5,422 -10,566	-66%	-$332K	﹤0.01%	960
2020 Q2	$521K	Buy	+15,988	New	+$487K	0.01%	779

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's BBIO Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 63,180 shares worth $4.69M. The stake represents 0.02% of the portfolio and ranks #428 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in BBIO as recently as Q4 2022.

Jacobs Levy Equity Management first reported a position in BBIO in Q2 2020 and has held it in 6 quarters since. The position peaked at $11.9M in Q3 2022. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Jacobs Levy Equity Management held 63,180 shares of BridgeBio Pharma worth $4.69M as of Q1 2026.
BridgeBio Pharma was a new Jacobs Levy Equity Management position in Q1 2026.
BridgeBio Pharma made up 0.02% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #428 holding.
Jacobs Levy Equity Management first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 6 quarters since.
Jacobs Levy Equity Management's BridgeBio Pharma position peaked at $11.9M in Q3 2022.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.